Not a good buy right now for an impatient trader: price is weak intraday (-5.67%) and sits below the pivot (11.407), with downside risk toward 10.59/10.09 support.
No Intellectia buy signals (AI Stock Picker and SwingMax both show no signal), removing the main “strong buy” priority triggers.
The bull case is mostly event/clinical optionality (SIM0505) and a single bullish analyst upgrade; fundamentals remain loss-making with no revenue, and volatility is extreme.
Best stance now: HOLD/AVOID new entry until price reclaims ~11.41 and/or momentum improves; otherwise odds favor a choppy-to-down tape near support.
Technical Analysis
Trend/Momentum: MACD histogram -0.131 (below zero) = bearish momentum; “negatively contracting” suggests selling pressure is easing but not reversed.
RSI(6) 44.66 = neutral-to-slightly weak; not oversold enough to imply a high-conviction bounce.
Moving averages converging = no clear uptrend; consolidation after weakness.
Levels: Pivot 11.407 (near-term line in the sand). Resistance: 12.222 then 12.726. Support: 10.591 then 10.088.
Pattern-based forward view (provided): ~90% chance of -0.34% next day, +3.25% next week, +6.04% next month → mild positive drift, but near-term still fragile.
Put/Call ratios at 0.0 strongly suggest minimal/absent reported put activity (and likely thin options liquidity), so options sentiment here is not very informative.
Historical volatility shown as 738.42 (extremely high) → market is pricing large swings; this increases the chance of sharp drawdowns around catalysts.
Missing/blank IV/volume fields also points to limited actionable options-flow insight for timing a buy.
Technical Summary
Sell
7
Buy
3
Positive Catalysts
with $18 PT citing SIM0505 “clear roadmap” to best-in-class ADC targeting CDH6 in advanced solid tumors.
Neutral/Negative Catalysts
Price action is currently bearish/unstable (down -5.67% today) and below the pivot; failure to hold 10.59 could open further downside.
No recent news this week to explain/offset the selloff; weakness may be flow/liquidity-driven.
Extremely high volatility (HV ~738%) + micro-cap profile (market cap ~$40.35M) increases gap risk and potential dilution concerns.
No notable hedge fund or insider accumulation signals recently (both neutral).
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no operating revenue base).
Profitability: Net loss worsened to -$8.624M (down -25.27% YoY).
EPS: -3.22 (down -34.95% YoY) → negative trend in per-share losses, consistent with ongoing cash burn.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: (2025-11-07) Ladenburg upgraded NXTC to Buy from Neutral; set $18 price target.
Wall Street-style pros: differentiated oncology pipeline optionality (SIM0505 ADC thesis) and high upside if clinical progress validates the target.
Cons: fundamentals are still pre-revenue with worsening losses; execution/financing risk is high, and near-term tape is weak—so the bullish PT is highly catalyst-dependent.
Net take: analyst view is optimistic on pipeline, but current market/technical setup does not support chasing a buy today.
Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 17.67 USD with a low forecast of 15 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 17.67 USD with a low forecast of 15 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.090
Low
15
Averages
17.67
High
20
Current: 11.090
Low
15
Averages
17.67
High
20
Ladenburg
Neutral -> Buy
upgrade
$18
AI Analysis
2025-11-07
Reason
Ladenburg
Price Target
$18
AI Analysis
2025-11-07
upgrade
Neutral -> Buy
Reason
Ladenburg upgraded NextCure to Buy from Neutral with an $18 price target. The firm says SIM0505 has a "clear roadmap" to become a "best-in-class" antibody drug conjugate that targets CDH6 for the treatment of advanced solid tumors.
Piper Sandler
Edward Tenthoff
Overweight
downgrade
$36 -> $15
2025-07-15
Reason
Piper Sandler
Edward Tenthoff
Price Target
$36 -> $15
2025-07-15
downgrade
Overweight
Reason
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on NextCure to $15 from $36 and keeps an Overweight rating on the shares. The firm notes NextCure exercised a 12-for-1 reverse stock split effective July 14th. Piper estimates NextCure now has 2.338 million shares outstanding and trades at an $11.5M market cap.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NXTC
